Formulary Drug Reviews: Nirsevimab
- Terri Levien; Daniel Baker
Access Resources
About
This article discusses the Formulary Drug Reviews on nirsevimab, a monoclonal antibody for preventing respiratory syncytial virus (RSV) in newborns and infants. It covers the drug's indications, clinical pharmacology, pharmacokinetics, comparative efficacy with palivizumab, and study results. The review provides insights into the drug's efficacy, safety, resistance, and recommendations from guidelines like ACIP and AAP, emphasizing its use for high-risk infants and children during RSV seasons.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.